Showing 901-910 of 2876 results for "".
- Coming This Week: Cutera AviClear Webinarhttps://modernaesthetics.com/news/coming-this-week-cutera-aviclear-webinar/2473230/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- Elevai Labs Names Chief Marketing and Brand Advisorhttps://modernaesthetics.com/news/elevai-labs-names-chief-marketing-and-brand-advisor/2473228/Brenda Buechler is now Chief Marketing and Brand Advisor for Elevai Labs, Inc. Elevai is a science-based aesthetic skincare company providing topical formulations featuring by ethically sourced, human umbilical mesenchymal stem cells (hUMSC)-derived e
- New from Lumenis: triLift Targets Three Elements of Aginghttps://modernaesthetics.com/news/new-form-lumenis-trilift-targets-three-elements-of-aging/2473227/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- Cutera Invites ASLMS Attendees to Celebrate AviClear Launchhttps://modernaesthetics.com/news/cutera-invites-aslms-attendees-to-celebrate-aviclear-launch/2473222/Cutera is celebrating the launch of AviClear during the ASLMS meeting in San Diego, and meeting attendees are invited to join the festivities. AviClear is the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, The AviClear laun
- Study: Skin of Color Patients Are Under-represented in Cosmetic Clinical Trialshttps://modernaesthetics.com/news/study-skin-of-color-patients-are-under-represented-in-cosmetic-clinical-trials/2473221/There’s a lack of ethnic/racial diversity in industry-sponsored aesthetic trials, according to new research in the April 2022 issue of Lasers in Surgery and Medicine. Researchers, led by Lisa Akintilo MD, MPH a current PGY-4 dermatology resident at New York
- Happy 20th Birthday Botox Cosmetic!https://modernaesthetics.com/news/happy-20th-birthday-botox-cosmetic/2473218/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Study: Sick Patients Get Cosmetic Surgery to Look Healthierhttps://modernaesthetics.com/news/study-sick-patients-get-cosmetic-surgery-to-look-healthier/2473216/Patients dealing with serious illnesses may want cosmetic procedures to make them look healthier, reports a small new Northwestern Medicine study. The patients believe cosmetic surgery may help them feel better in social situations with their friends, family or when they’re at work. &n
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- PatientFi, Allergan Expand Co-marketing Agreementhttps://modernaesthetics.com/news/patientfi-allergan-expand-co-marketing-agreement/2473214/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Aquavit's Neurotoxin Submitted to FDAhttps://modernaesthetics.com/news/aquavits-neurotoxin-submitted-to-fda/2473213/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende